Page last updated: 2024-12-06

isocoumarins

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isocoumarins: Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isocoumarin : The simplest member of the class of isocoumarins that is 1H-isochromene which is substituted by an oxo group at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68108
CHEMBL ID457811
CHEBI ID38759
SCHEMBL ID76183
MeSH IDM0471145

Synonyms (23)

Synonym
1h-2-benzopyran-1-one
isocoumarin
isochromen-1-one
CHEMBL457811
chebi:38759 ,
491-31-6
AKOS006285714
benzoic acid, 2-(2-hydroxyethenyl)-, delta-lactone
sr89982s3e ,
unii-sr89982s3e
isocoumarins
3,4-benzo-2-pyrone
1h-isochromen-1-one
FT-0607868
SCHEMBL76183
DTXSID8060080
IQZZFVDIZRWADY-UHFFFAOYSA-N
N10038
Q412756
mfcd08061387
AS-76786
EN300-6487432
Z1198175817

Research Excerpts

Effects

ExcerptReferenceRelevance
"Four isocoumarins have been isolated from the terrestrial Streptomyces sp. "( Bioactive isocoumarins from a terrestrial Streptomyces sp. ANK302.
Abdalla, MA; Islam, MT; Laatsch, H; Schüffler, A; Shaaban, KA; Zinad, DS, 2011
)
1.29

Pharmacokinetics

ExcerptReferenceRelevance
" Here, we systematically characterize the pharmacokinetic and pharmacodynamics properties of the SMN splicing modifier SMN-C1."( Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
Chen, KS; Dakka, A; Feng, Z; Karp, G; Ko, CP; Ling, KK; Lotti, F; Metzger, F; Mollin, A; Narasimhan, J; Naryshkin, NA; Paushkin, S; Pellizzoni, L; Petruska, J; Ratni, H; Sheedy, J; Tisdale, S; Weetall, M; Welch, EM; Yeh, S; Zhao, X, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" The present work has assessed the activity of NM-3 against human non-small-cell lung cancer (NSCLC) cells when used alone and in combination with docetaxel."( The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Agata, N; Bamberg, M; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H; Pu, M; Weitman, S, 2005
)
0.33
"To investigate the effects of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3) alone and in combination with carboplatin on tumor growth and apoptosis in mouse models of human gastric cancer constructed by subcutaneous implantation of histologically intact tumor tissue."( Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM, 2007
)
0.34
" NM-3 was injected peritoneally at the dose of 10 mg/kg, 20 mg/kg or 40 mg/kg every other day for 5 wk, combined with carboplatin (5 mg/kg) every third day for 4 wk."( Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM, 2007
)
0.34
" But NM-3 in combination with carboplatin had greater effects of tumor weight than either NM-3 or carboplatin alone."( Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM, 2007
)
0.34
" Furthermore, NM-3 alone at the dose of 10 mg/kg or in combination with carboplatin has no obvious effects on body changes, indicating that NM-3 in combination with carboplatin may be effective in the treatment of gastric cancer."( Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivo.
Chen, JL; Chen, MX; Chen, NW; Chen, WX; Hong, J; Lu, JL; Shen, B; Zhu, JS; Zhu, ZM, 2007
)
0.34
" However, 5-formylisochromen-1-one (4), (-)-mellein (8), and swermacrolactone C (9) exhibited potent antimycobacterial activities against Mycobacterium smegmatis when used in combination with the antibiotic drug erythromycin."( Constituents of Fagraea fragrans with Antimycobacterial Activity in Combination with Erythromycin.
Chakthong, S; Cheyeng, N; Chusri, S; Heembenmad, S; Madmanang, S; Mahabusarakam, W; Saising, J; Seeger, M, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" The bioavailability and nontoxic profile of NM-3 suggests that the efficacy of this agent should be tested in clinical radiotherapy."( NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity.
Beckett, MA; Gupta, VK; Hari, DM; Hellman, S; Jaskowiak, NT; Kalluri, R; Koons, AM; Kufe, DW; Mauceri, HJ; Posner, MC; Reimer, C; Salloum, RM; Seetharam, S; Weichselbaum, RR, 2000
)
0.31
"2-(8-Hydroxy-6-methoxy-1-oxo-1Eta-2-benzopyran-3-yl)propionic acid (NM-3) is a small molecule isocoumarin derivative that has recently entered clinical trials as an orally bioavailable anticancer agent."( 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.
Agata, N; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H, 2004
)
0.32
"The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1 H-2-benzopyran-3-yl) propionic acid (NM-3) has completed phase I clinical evaluation as an orally bioavailable angiogenesis inhibitor."( The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel.
Agata, N; Bamberg, M; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H; Pu, M; Weitman, S, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
"An exclusive trans-aminocarboxylation and oxoaminocarboxylation of diarylalkynes were realized through hypervalent iodine-mediated cascade annulations under metal-free conditions, leading to divergent assembly of fused or spiro polycyclic heterocycles with a dosage of the hypervalent iodine oxidant."( Hypervalent Iodine-Mediated Intramolecular trans-Aminocarboxylation and Oxoaminocarboxylation of Alkynes: Divergent Cascade Annulations of Isocoumarins under Metal-Free Conditions.
Du, Y; Hou, W; Zhang, X; Zhang-Negrerie, D; Zhao, K, 2015
)
0.62
" Mice treated with galloflavin also showed a dose-response increase in survival."( Pyruvate dehydrogenase complex and lactate dehydrogenase are targets for therapy of acute liver failure.
Brunetti-Pierri, N; Carissimo, A; De Cegli, R; Ferriero, R; Manco, G; Nusco, E, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isocoumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID399186Antifungal activity against Cladosporium herbarum assessed as inhibition zone in mycelial layer assessed per spot by TLC bioautography assay2004Journal of natural products, Jan, Volume: 67, Issue:1
Antifungal 3-butylisocoumarins from Asteraceae-Anthemideae.
AID399185Antifungal activity against Pyricularia grisea assessed as inhibition of germ-tube development by microdilution method2004Journal of natural products, Jan, Volume: 67, Issue:1
Antifungal 3-butylisocoumarins from Asteraceae-Anthemideae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (545)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (3.49)18.7374
1990's94 (17.25)18.2507
2000's110 (20.18)29.6817
2010's247 (45.32)24.3611
2020's75 (13.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.53 (24.57)
Research Supply Index6.32 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.18%)5.53%
Reviews20 (3.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other534 (96.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]